Non-Invasive Biomarker Monitoring in UC on Biologics (VIBRANT)

  • Research type

    Research Study

  • Full title

    Prospective Evaluation of Exhaled Volatile Organic Compounds, Faecal and Blood Biomarkers, and Epigenetic Profiles to Predict Remission and Relapse in Ulcerative Colitis Patients Receiving Intravenous Biologic Therapy

  • IRAS ID

    372037

  • Contact name

    Ramesh Arasaradnam

  • Contact email

    ramesh.arasaradnam@warwick.ac.uk

  • Sponsor organisation

    UHCW NHS Trust

  • Duration of Study in the UK

    1 years, 6 months, 31 days

  • Research summary

    Ulcerative colitis (UC) is a long-term condition that causes inflammation in the large bowel. Many patients need strong medicines called biologic drugs, given by drip (intravenous infusion) every few weeks. Currently, doctors check whether these drugs are working using blood tests and stool samples. These tests can be uncomfortable and the results are not always immediate.This study, called VIBRANT, will test whether a simple breath test can help doctors monitor how well the biologic treatment is working in patients with UC. We will also look at stool samples, blood tests, and other markers to see if we can better predict who will stay well in remission and who might have a flare-up (relapse).We will invite around 110 adults with UC who are already receiving regular intravenous biologic infusions at University Hospitals Coventry and Warwickshire. Participants will give a breath sample, a small blood sample, and a stool sample during their routine infusion clinic visits (at the start, and then at 8, 16, and 24 weeks). These visits are part of their normal care, so no extra hospital trips are needed.The breath samples will be analysed for chemicals called volatile organic compounds (VOCs). We will compare these breath results with standard blood and stool tests to see if the breath test can reliably show whether the treatment is working.The study will not change anyone’s treatment. It aims to develop better, non-invasive ways to monitor UC in the future, so patients can receive more personalised care and avoid unnecessary flare-ups.

  • REC name

    Wales REC 7

  • REC reference

    26/WA/0201

  • Date of REC Opinion

    16 Jul 2026

  • REC opinion

    Favourable Opinion